Back to Search
DANIEL MARQUIS, PHARMD
PHARMD
Pediatric Pharmacist
NPI: 1669245668Individual
Specialties, Licenses & Credentials
Pediatric PharmacistPrimary
Pharmacist — Pediatrics
Code: 1835P0200X
PS58101(FL)PH200004391(DC)
Research & Publications (13)
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.
PMID 19519691·Br J Haematol·2009
3-trial
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.
PMID 19344412·Br J Haematol·2009
3-trial
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
PMID 18504251·Ann Oncol·2008
3-trial
The need for specialty curricula based on core competencies: a white paper of the Conjoint Committee on Continuing Medical Education.
PMID 17576626·J Contin Educ Health Prof·2007
8-other
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.
PMID 16825493·Blood·2006
4-observational
[Breast cancer screening programme: a media campaign for isolated or marginalised women].
PMID 16485435·Sante Publique·2005
8-other
A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma.
PMID 12679797·Cancer Gene Ther·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 111 MICHIGAN AVE NW
WASHINGTON, DC 20010 - Phone
- (407) 415-5001
Quick Facts
- NPI
- 1669245668
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile